At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
MEDI2070 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy
In Brief
A Phase 2 clinical trial evaluating MEDI2070 and placebo for Crohn's Disease. Completed, enrolled 121 participants across 80 sites in 9 countries.
Detailed Summary
The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection in open-label period
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesCanada, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United States
CollaboratorsMedImmune Ltd
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartFeb 2013
Primary CompletionMay 2014
Study CompletionDec 2016
TodayJul 2026
First PostedOct 26, 2012
Enrollment StartFeb 1, 2013
Primary CompletionMay 20, 2014
Study CompletionDec 14, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.7 years ago
Interventions
MEDI2070drug
1 iv infusion on Week 0 and Week 4
placebodrug
1 iv infusion on Week 0 and Week 4